SCHEMBL1657155

SCHEMBL1657155

CS(=O)(=O)c1ccc(O)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.48
ENPP2 Q13822 1/20 0.45
TTR P02766 2/20 0.42
POLB P06746 1/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
ESR1 P03372 5/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
AR P10275 1/20 0.39
CNR2 P34972 1/20 0.38
ESR2 Q92731 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGS1 P23219 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364296 0.83 HSD17B10 (0.48) HSD17B10ENPP2POLBCA12CA1
SCHEMBL69469 0.83 HSD17B10 (0.52) HSD17B10TTRPOLBESR1CA12
SCHEMBL15880399 0.81 TRPV4 (0.53) HSD17B10TTRPOLBESR1CA12
SCHEMBL1808946 0.81 HSD17B10 (0.50) HSD17B10TTRPOLBESR1CA12
Hydrochloric Acid SCHEMBL28047309 0.79 HSD17B10 (0.48) HSD17B10TTRPOLBESR1CA12
SCHEMBL1805100 0.79 CA1 (0.50) HSD17B10POLBESR1CA12CA1
SCHEMBL20488864 0.79 ALDH1A1 (0.51) HSD17B10
SCHEMBL1625796 0.78 CCR2 (0.51)
SCHEMBL9336134 0.78 ENPP2 (0.48) HSD17B10ENPP2POLBCA12CA1
SCHEMBL12186139 0.77 L3MBTL1 (0.44) PIK3CDPIK3CAPIK3CBPIK3CGCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1905769-B1 HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2017-03-29 EP disclosed
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2014-03-06 US disclosed
EP-1810969-B1 ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES MSD KK (JP) 2013-08-07 EP disclosed
WO-2013105753-A1 SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-07-18 WO disclosed
WO-2013105753-A1 SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME HYUNDAI PHARM CO., LTD. (KR) 2013-07-18 WO disclosed
WO-2012145361-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2012-10-26 WO disclosed
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP disclosed
EP-2377863-A1 Piperidine GPCR agonists Prosidion Limited (GB) 2011-10-19 EP disclosed
EP-2114933-B1 PIPERIDINE GPCR AGONISTS PROSIDION LTD (GB) 2011-09-07 EP disclosed
US-7994331-B2 Heterocycle-substituted benzimidazole derivative MSD K.K. (JP) 2011-08-09 US disclosed
US-20080125429-A1 Aryloxy-Substituted Benzimidazole Derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-05-29 US disclosed
EP-1905769-A1 HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-02 EP disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
CN-101094847-A Aryloxy-substituted benzimidazole derivatives BANYU PHARMA CO LTD (JP) 2007-12-26 CN disclosed
EP-1810969-A1 ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-07-25 EP disclosed
CN-1926127-A Novel 2-heteroaryl substituted benzimidazole derivatives BANYU PHARMA CO LTD (JP) 2007-03-07 CN disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative MSD K.K. (JP) 2006-07-27 US disclosed
CN-1777589-A Heteroarylcarbamoylbenzene derivatives BANYU PHARMA CO LTD (JP) 2006-05-24 CN disclosed
EP-1600442-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125429-A1 Aryloxy-Substituted Benzimidazole Derivatives GCK, GCKR, SLC5A1 HSD17B10 2116/4885ENPP2 3695/4885TTR 2561/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 HSD17B10 1084/4885ENPP2 3278/4885TTR 2993/4885
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative GCK, GCKR, GALK1 HSD17B10 150/4885ENPP2 2273/4885TTR 2560/4885
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto GPR119, GLP1R, SLC5A2 HSD17B10 1217/4885ENPP2 623/4885TTR 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.